165
Participants
Start Date
October 31, 2007
Primary Completion Date
August 31, 2009
Study Completion Date
December 31, 2010
INT-747
Once a day (QD) by mouth (PO)
Ursodeoxycholic Acid (URSO)
Stable dose for at least 6 months prior to screening. Dose as prescribed by physician.
Placebo
Placebo
Erasmus Medical Centre, Rotterdam
Beth Israel Medical Center, New York
Mt. Sinai School of Medicine, New York
McGuire DVAMC, Richmond
Medical School of Hannover, Hanover
U Florida Hepatology, Gainesville
University of Miami - Center for Liver Diseases, Miami
Cleveland Clinic, Cleveland
Henry Ford Health Center Columbus, Novi
Johann Wolfgang Goethe University, Frankfurt
Saint Louis University, St Louis
Hopital de l'Hotel Dieu, Lyon
UT Southwestern Medical Center, Dallas
Baylor College of Medicine, Houston
Virginia Mason Medical Center, Seattle
Mayo Clinic, Rochester
Tufts Medical Center, Boston
Karls-Franzens University, Graz
University of Calgary, Calgary
University of Alberta, Edmonton
University of Manitoba, Winnipeg
University of Toronto Western Hospital, Toronto
Centre de Recherche du CHUM / University of Montreal, Montreal
University Medical Centre Hamburg-Eppendorf, Hamburg
University of Munich, Munich
AMC University of Amsterdam, Amsterdam
Hospital Clinic i Provincial, Barcelona
Queen Elizabeth Medical Center, Edgbaston
Royal Free Hospital, Hampstead
John Radcliffe Hospital, Headington
Royal Infirmary, Edinburgh
University Upon Tyne/Newcastle, Newcastle upon Tyne
Lead Sponsor
Intercept Pharmaceuticals
INDUSTRY